Logo image of EQ

EQUILLIUM INC (EQ) Stock Overview

NASDAQ:EQ - US29446K1060 - Common Stock

1.91 USD
+0.16 (+9.14%)
Last: 9/5/2025, 8:10:10 PM
1.94 USD
+0.03 (+1.57%)
After Hours: 9/5/2025, 8:10:10 PM

EQ Key Statistics, Chart & Performance

Key Statistics
52 Week High2.35
52 Week Low0.27
Market Cap113.64M
Shares59.50M
Float46.56M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.56
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11
IPO10-12 2018-10-12
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


EQ short term performance overview.The bars show the price performance of EQ in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 100 200 300 400

EQ long term performance overview.The bars show the price performance of EQ in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100 150

The current stock price of EQ is 1.91 USD. In the past month the price increased by 245.39%. In the past year, price increased by 106.26%.

EQUILLIUM INC / EQ Daily stock chart

EQ Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.07 375.50B
AMGN AMGEN INC 13.01 152.70B
GILD GILEAD SCIENCES INC 14.86 142.76B
VRTX VERTEX PHARMACEUTICALS INC 23.38 101.56B
REGN REGENERON PHARMACEUTICALS 12.56 60.77B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 80.99 45.95B
ONC BEONE MEDICINES LTD-ADR 5.99 40.63B
INSM INSMED INC N/A 30.67B
BNTX BIONTECH SE-ADR N/A 27.03B
NTRA NATERA INC N/A 23.06B
BIIB BIOGEN INC 8.79 20.62B

About EQ

Company Profile

EQ logo image Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 35 full-time employees. The company went IPO on 2018-10-12. The company is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.

Company Info

EQUILLIUM INC

2223 Avenida de La Playa Ste 105

La Jolla CALIFORNIA 92037 US

CEO: Bruce D. Steel

Employees: 35

EQ Company Website

EQ Investor Relations

Phone: 18584125302

EQUILLIUM INC / EQ FAQ

What is the stock price of EQUILLIUM INC today?

The current stock price of EQ is 1.91 USD. The price increased by 9.14% in the last trading session.


What is the ticker symbol for EQUILLIUM INC stock?

The exchange symbol of EQUILLIUM INC is EQ and it is listed on the Nasdaq exchange.


On which exchange is EQ stock listed?

EQ stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EQUILLIUM INC stock?

11 analysts have analysed EQ and the average price target is 2.55 USD. This implies a price increase of 33.51% is expected in the next year compared to the current price of 1.91. Check the EQUILLIUM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EQUILLIUM INC worth?

EQUILLIUM INC (EQ) has a market capitalization of 113.64M USD. This makes EQ a Micro Cap stock.


How many employees does EQUILLIUM INC have?

EQUILLIUM INC (EQ) currently has 35 employees.


What are the support and resistance levels for EQUILLIUM INC (EQ) stock?

EQUILLIUM INC (EQ) has a support level at 1.74 and a resistance level at 1.92. Check the full technical report for a detailed analysis of EQ support and resistance levels.


Is EQUILLIUM INC (EQ) expected to grow?

The Revenue of EQUILLIUM INC (EQ) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EQ EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EQUILLIUM INC (EQ) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EQUILLIUM INC (EQ) stock pay dividends?

EQ does not pay a dividend.


When does EQUILLIUM INC (EQ) report earnings?

EQUILLIUM INC (EQ) will report earnings on 2025-11-11.


What is the Price/Earnings (PE) ratio of EQUILLIUM INC (EQ)?

EQUILLIUM INC (EQ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).


What is the Short Interest ratio of EQUILLIUM INC (EQ) stock?

The outstanding short interest for EQUILLIUM INC (EQ) is 7.05% of its float. Check the ownership tab for more information on the EQ short interest.


EQ Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to EQ. When comparing the yearly performance of all stocks, EQ is one of the better performing stocks in the market, outperforming 99.13% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

EQ Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to EQ. The financial health of EQ is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EQ Financial Highlights

Over the last trailing twelve months EQ reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS decreased by -124% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -162.87%
ROE -399.41%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1700%
Sales Q2Q%-100%
EPS 1Y (TTM)-124%
Revenue 1Y (TTM)-61.16%

EQ Forecast & Estimates

11 analysts have analysed EQ and the average price target is 2.55 USD. This implies a price increase of 33.51% is expected in the next year compared to the current price of 1.91.

For the next year, analysts expect an EPS growth of -280.65% and a revenue growth -100% for EQ


Analysts
Analysts81.82
Price Target2.55 (33.51%)
EPS Next Y-280.65%
Revenue Next Year-100%

EQ Ownership

Ownership
Inst Owners19.74%
Ins Owners24.24%
Short Float %7.05%
Short Ratio0.34